|Articles|April 10, 2003
Phase III shaping up - Enrollment completed in final CK clinical trial
Irvine, CA-Refractec Inc. has completed patient enrollment for its phase III clinical trial for conductive keratoplasty (CK) as a treatment for presbyopia.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approvals in 2025: What changed and why it matters for ophthalmologists
2
PRIMAvera study: Central vision improvement with subretinal implant
3
Q&A: What changed in residency education in 2025? Perspectives from training directors
4
Refractory dry eye care: How systemic conditions change the game
5